Perturbed neuronal calcium homeostasis is a prominent feature in Alzheimer's disease (AD). Mitochondria accumulate calcium ions (Ca 2+ ) for cellular bioenergetic metabolism and suppression of mitochondrial motility within the cell. Excessive Ca 2+ uptake into mitochondria often leads to mitochondrial membrane permeabilization and induction of apoptosis. Ca 2+ is an interesting second messenger which can initiate both cellular life and death pathways in mitochondria. This review critically discusses the potential of manipulating mitochondrial Ca 2+ concentrations as a novel therapeutic opportunity for treating AD. This review also highlights the neuroprotective role of a number of currently available agents that modulate different mitochondrial Ca 2+ transport pathways. It is reasoned that these mitochondrial Ca 2+ modulators are most effective in combination with agents that increase the Ca 2+ buffering capacity of mitochondria. Modulation of mitochondrial Ca 2+ handling is a potential pharmacological target for future development of AD treatments.
a b s t r a c t
Perturbed neuronal calcium homeostasis is a prominent feature in Alzheimer's disease (AD). Mitochondria accumulate calcium ions (Ca 2+ ) for cellular bioenergetic metabolism and suppression of mitochondrial motility within the cell. Excessive Ca 2+ uptake into mitochondria often leads to mitochondrial membrane permeabilization and induction of apoptosis. Ca 2+ is an interesting second messenger which can initiate both cellular life and death pathways in mitochondria. This review critically discusses the potential of manipulating mitochondrial Ca 2+ concentrations as a novel therapeutic opportunity for treating AD. This review also highlights the neuroprotective role of a number of currently available agents that modulate different mitochondrial Ca 2+ transport pathways. It is reasoned that these mitochondrial Ca 2+ modulators are most effective in combination with agents that increase the Ca 2+ buffering capacity of mitochondria. Modulation of mitochondrial Ca 2+ handling is a potential pharmacological target for future development of AD treatments.
© 2010 Elsevier B.V. All rights reserved.
Introduction
As the average life span of human population gradually increases, the prevalence of age-related diseases has significantly increased. Alzheimer's disease (AD) is a fatal neurodegenerative disorder, affecting approximately 35.6 million people worldwide (Prince and Jackson, 2009). AD is the most common form of dementia. The disease is characterized by progressive synaptic dysfunction and neuronal loss in various brain regions, especially in the cortex and hippocampus. Severe neurodegeneration in these brain regions results in cognitive, emotion, social and motor impairments. With more than a 100 years of research, the underlying mechanism of this incurable disease still remains elusive. Perturbed neuronal calcium (Ca 2+ ) homeostasis is a common feature in many neurodegenerative diseases including AD, amyotrophic lateral sclerosis (ALS), ischemic stroke and Parkinson's disease (PD) (Mattson and Chan, 2003) . Increasing lines of evidence support the idea that Ca 2+ dysregulation plays a key role in AD pathogenesis
Neuronal Ca 2+ dysregulation and Alzheimer's disease
Ca 2+ signaling is essential for life and death processes including neuronal excitability, synaptic plasticity, gene transcription and apoptosis (Berridge, 1998; Berridge et al., 1998) . The Ca 2+ dysregulation hypothesis postulates that sustained increase in cytosolic Ca 2+ concentrations can lead to neurodegeneration in AD (Khachaturian, 1994; Toescu and Verkhratsky, 2007) . Disturbances in Ca 2+ signaling have been found in both sporadic and familial cases of AD (LaFerla, 2002) . Several age-related perturbations in pathways regulating Ca 2+ homeostasis have been reported, suggesting a possible linkage between aging and the development of sporadic AD (Bezprozvanny, 2009) . A small proportion of AD patients (∼5%) suffer from an early-onset familial form that occurs under age of 65 (Hardy, 2006) . The genes involved in familial AD include presenilins (presenilin 1 and 2) and amyloid precursor protein (APP) (Hardy and Gwinn-Hardy, 1998) . Both have been shown to play important roles in Ca 2+ signaling (LaFerla, 2002) . The mechanisms of how Ca 2+ homeostasis is disrupted in AD have been extensively reviewed (Bezprozvanny, 2009; Bojarski et al., 2008; LaFerla, 2002; Mattson and Chan, 2003; Yu et al., 2009 ). In the fol-
